Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 31st International Conference on Mental and Behavioral Health Tokyo, Japan.

Day 1 :

Keynote Forum

Joseph Rosado

Medical Director Med Diagnostic Inc., DBA Coastal Wellness Centers United States

Keynote: Medical Cannabis for Autism Spectrum Disorder

Time : 10:00

Mental Health Congress 2019 International Conference Keynote Speaker Joseph Rosado photo

After spending several years in central Florida working as an orderly, then an EMT/Paramedic and Heart Cath Lab technician, Dr. Rosado realized his passion for the medical profession. He started chiropractic school at Life College in Marietta, GA where he graduated cum laude with a BS degree in Clinical Nutrition and a doctor of chiropractic degree. After practicing for several years, he went on to Universidad Central del Este, in San Pedro de Macoris where in 2001 he graduated summa cum laude with his medical degree. In 2005 he completed his MBA in Health Care Management from University of Phoenix, and graduated magna cum laude.

He has worked as a physician, clinic and hospital director, director of the communicable disease division/epidemiology and immunization departments. Presently, Dr. Rosado is the Medical Director of a medical cannabis clinic and volunteers once a month at a community clinic.

He was and is on the bureau of speakers for political campaigns, cannabis advocacy and medical cannabis dispensaries/licensed producers. He has worked with toddlers, children, adolescents, adults and geriatric patients for the recommendation of and management with medical cannabis and is a Diplomate of the American Academy of Cannabinoid Medicine



OBJECTIVE: A literature review was conducted to evaluate the validity of medical cannabis as an adjunctive treatment in the management of individuals with Autism Spectrum Disorders.

BACKGROUND: Autism spectrum disorder (ASD) is a developmental disability that can cause significant social, communication and behavioral challenges. The learning, thinking, and problem-solving abilities of people with ASD can range from gifted to severely challenged.

Since there is no medical test to diagnose the disorders, the provider must listen to the parent/ caretaker and look at the child’s behavior and development to make a diagnosis. Unfortunately, many children do not receive a final diagnosis until much older.

A deficiency in the endocannabinoid system in the body is considered as the reason for many disorders and recent researchers’ state that it might help in the treatment of autism. The chronic neuroinflammation can be eased with the help of the antioxidants which are present in the cannabis plant.

The theory of CED was based on the concept that many brain disorders are associated with neurotransmitter deficiencies, affecting acetylcholine in Alzheimer's disease, dopamine in Parkinsonian Syndromes, serotonin and norepinephrine in depression, and that a comparable deficiency in endocannabinoid levels might be manifest similarly in certain disorders that display predictable clinical features as sequelae of this deficiency.

DESIGN/METHODS: A literature review was conducted of the National Center for Biotechnology InformationU.S. National Library of Medicine PubMed from 2012-2018 specific to the topic of medical cannabis and autism spectrum disorder.

CONCLUSION: This literature review supports the feasibility of cannabis based medicine as a promising treatment option in children with ASD. Based on the promising results, it is recommended that large, double blind, placebo controlled cross-over trials be launched in jurisdictions where medical cannabis can be studied without limitations from the federal government.